CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD Total Non-current Liabilities
All obligations due after more than one year.
CONMED CorporationNYSE: CNMD
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 3.1% from a year ago
Total non-current liabilities stood at $1B at the end of Q1 FY2026, down 3.1% from a year earlier and up 2.8% from the prior quarter. Over 3 fiscal years it compounded at -8.0% a year.
Context
- Total non-current liabilities amounted to 43.4% of total assets at the end of Q1 FY2026, down 1.7 pp from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -3.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 977.61M USD
- Year-over-year change
- -8.2%
- 4-year CAGR
- +5.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 977.61M | -8.2% |
| FY2024 | 2024-12-31 | 1.07B | -7.8% |
| FY2023 | 2023-12-31 | 1.16B | -8.0% |
| FY2022 | 2022-12-31 | 1.26B | +60.2% |
| FY2021 | 2021-12-31 | 783.94M | — |
Total Non-current Liabilities vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's Mar 2026 total non-current liabilities of $1B is the 3rd highest of the 11 companies compared; the peer median is $109.63M.
- Its year-over-year change of -3.1% is the 4th highest of 11, against a peer median of -4.7%.
- Total non-current liabilities amounts to 43.4% of total assets for CNMD, versus a peer median of 16.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Apr 2026 | $2.17B | -5.3% | -7.3% | 49.0% | |
| Aug 2026 | $1.07B | -4.1% | -4.9% | 32.3% | |
| Mar 2026 | $1B | -3.1% | -8.0% | 43.4% | |
| Sep 2026 | $271.67M | +8.4% | +11.7% | 75.7% | |
| Mar 2026 | $239.63M | +66.9% | -25.9% | 30.4% | |
| Jun 2026 | $141.18M | -21.6% | +25.4% | 20.7% | |
| Sep 2026 | $78.08M | -17.7% | -17.7% | 4.6% | |
| Mar 2026 | $61.4M | -34.4% | -24.9% | 8.1% | |
| Jan 2026 | $48.42M | -85.2% | — | 12.8% | |
| Mar 2026 | $12.23M | -3.3% | +17.1% | 1.6% | |
| Mar 2026 | $9.98M | +26.2% | +72.8% | 11.0% | |
| Peer median (excluding CNMD) | $109.63M | -4.7% | -4.9% | 16.7% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.85M | 28.94M | 24.3M | 24.46M | 40.82M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 183.88M | 191.35M | 242.28M | 237.73M | 247.83M |
| Inventory | 231.64M | 332.32M | 318.32M | 346.72M | 355.54M |
| Other Current Assets | 4.9M | 28.62M | 30.75M | 31.1M | 28.67M |
| Total Current Assets | 460.12M | 581.23M | 615.65M | 640.01M | 672.86M |
| Property, Plant & Equipment (Net) | 108.86M | 115.61M | 120.72M | 115.79M | 113.33M |
| Goodwill | 617.53M | 815.43M | 806.84M | 805.36M | 807.01M |
| Intangible Assets | 471.05M | 681.8M | 649.48M | 617.66M | 582.05M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 9.66M | 9.65M | 11.21M | 11.07M | 13.31M |
| Other Non-current Assets | 98.8M | 93.88M | 96.11M | 116.36M | 137.19M |
| Total Non-current Assets | 1.31B | 1.72B | 1.68B | 1.67B | 1.65B |
| Total Assets | 1.77B | 2.3B | 2.3B | 2.31B | 2.33B |
| Account Payables | 58.2M | 73.39M | 88.22M | 102.25M | 93.65M |
| Short-term Debt | 12.25M | 69.75M | 8.22M | 715K | 712K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 126.2M | 153.41M | 138.07M | 175.17M | 220.68M |
| Total Current Liabilities | 196.65M | 296.55M | 310.73M | 278.13M | 315.04M |
| Long-term Debt | 672.41M | 985.08M | 971.48M | 905.07M | 834.23M |
| Deferred Tax Liabilities | 68.54M | 66.73M | 60.9M | 74.08M | 79.53M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 42.99M | 203.69M | 111.13M | 86.29M | 63.85M |
| Total Non-current Liabilities | 783.94M | 1.26B | 1.16B | 1.07B | 977.61M |
| Total Liabilities | 980.58M | 1.55B | 1.47B | 1.34B | 1.29B |
| Common Stock | 313K | 313K | 313K | 313K | 313K |
| Retained Earnings | 496.61M | 412.63M | 452.53M | 560.28M | 588.77M |
| Accumulated OCI | (54.2M) | (57.86M) | (50.17M) | (58.86M) | (46.3M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 785.44M | 745.55M | 834.22M | 962.68M | 1.03B |
| Total Debt | 684.66M | 1.05B | 991.25M | 905.78M | 834.94M |
| Net Debt | 663.81M | 1.03B | 966.96M | 881.32M | 794.13M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.